<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137121</url>
  </required_header>
  <id_info>
    <org_study_id>F170104006 (XUAB 16100)</org_study_id>
    <secondary_id>000515449</secondary_id>
    <nct_id>NCT03137121</nct_id>
  </id_info>
  <brief_title>Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients</brief_title>
  <official_title>Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patient - A Pilot, Dose-Finding Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer&#xD;
      patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a&#xD;
      randomized placebo-controlled pilot trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced cancer experience a variety of physical and psychosocial symptoms that&#xD;
      significantly affect the patients' quality of life. Chronic nausea is a particularly&#xD;
      distressing symptom present in &gt;60% of patients with advanced cancer. A number of palliative&#xD;
      care studies have evaluated treatments of nausea with limited success. Olanzapine with its&#xD;
      unique formulation and decreased drug interactions compared to many other drugs appears to be&#xD;
      a reasonable candidate for further evaluation. Olanzapine has significant potential for use&#xD;
      in the prevention and treatment of nausea in a palliative care setting with a once-daily&#xD;
      dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Actual">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 12, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There will be two groups for the study: Olanzapine Group will receive the study drug and Placebo Group will receive a placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Patients will receive the study drug or placebo in a double-blind fashion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Nausea Scores</measure>
    <time_frame>Nausea score from the Visual Analogue Scale will be recorded each day daily for 7 days. An average value calculated will be reported for the 7 day period.</time_frame>
    <description>Daily nausea scores (the primary objective) on day 1 to 7 of treatment for each patient from the Olanzapine and Placebo group will be measured using the Visual Analogue Scale rankings from 0-10 where 0 is no nausea and 10 is the maximum nausea experienced by a patient. A Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that can't be directly measured.&#xD;
Patients will be asked to record the average nausea score for each day in a diary and a study nurse will call the patient at the same time each day to remind the patient to record the nausea score and to inquire about any toxicities. The difference in the nausea scores for the patients in each group (Olanzapine and Placebo) will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Emetic Episodes</measure>
    <time_frame>Number of emetic episodes for each patient on each day of the seven day treatment.</time_frame>
    <description>The number of emetic episodes (a secondary outcome) by each patient in each group, Olanzapine &amp; Placebo, on each day of treatment will be recorded by each patient on each day of treatment in a diary. A study nurse will contact each patient at the same time of each day of the study to ask the patient to record the number of emetic episodes and report any toxicities.The number of emetic episodes for the patients in each Group for each day of the treatment will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-related Adverse Events as Assessed by CTCAE v4.0&quot;.</measure>
    <time_frame>Daily assessment for 7 days for each patient in Olanzapine &amp; Placebo Groups.</time_frame>
    <description>Adverse events will be measured by patient-reported outcomes questionnaires and the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A study nurse will contact each patient each day of the seven days of treatment to inquire about any toxicities, specifically sedation and appetite. Sedation and appetite will be reported by the patient in each Group on a Visual Analogue Scale of 0 to 10 with 0 being no sedation or no appetite to 10 indicating maximum sedation or maximum appetite.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a placebo orally for 1 to 7 days daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine is used as an anti-emetic.</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is a non-anti-emetic.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age&#xD;
&#xD;
          -  Have histologically or cytologically-confirmed malignant disease in an advanced&#xD;
             incurable stage&#xD;
&#xD;
          -  Have not received chemotherapy or radiation for &gt;14 days (advanced cancer patients&#xD;
             receiving hormonal therapy or targeted therapy that does not come with a&#xD;
             recommendation for prophylactic anti-emetic therapy are eligible)&#xD;
&#xD;
          -  Have chronic nausea that has been present for at least one week (worst daily score &gt;3,&#xD;
             0-10 visual analogue scale) or vomiting at least five times over past one week&#xD;
&#xD;
          -  Have serum creatinine &lt; 2.0 mg/dl and serum glutamic oxaloacetic transaminase (SGOT)&#xD;
             or serum glutamic pyruvic transaminase (SGPT) &lt; 3 times upper limits of normal â‰¤120&#xD;
             days prior to registration&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;1500 mm3 &lt;120 days prior to registration&#xD;
&#xD;
          -  Women of childbearing potential must consent to use adequate contraception throughout&#xD;
             protocol therapy; females of childbearing potential must have a negative urine&#xD;
             pregnancy test &lt;7 days prior to registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not be receiving treatment with another antipsychotic agent such as risperidone,&#xD;
             quetiapine, clozapine, phenothiazine or butyrophenone for less than or equal to 30&#xD;
             days prior to registration or planned during protocol therapy (patients may have&#xD;
             received prochlorperazine and other phenothiazines as prior anti-emetic therapy)&#xD;
&#xD;
          -  Not have concurrent use of ethyol&#xD;
&#xD;
          -  Not have severe cognitive compromise&#xD;
&#xD;
          -  History of central nervous system (CNS) disease (e.g. brain metastases, seizure&#xD;
             disorder)&#xD;
&#xD;
          -  Concurrent use of amifostine, concurrent abdominal radiotherapy; concurrent use of&#xD;
             quinolone antibiotic therapy&#xD;
&#xD;
          -  Chronic alcoholism (as determined by the investigator)&#xD;
&#xD;
          -  Known hypersensitivity to olanzapine&#xD;
&#xD;
          -  Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial&#xD;
             infarction within the previous six months&#xD;
&#xD;
          -  History of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral&#xD;
             hypoglycemic agent permitted)&#xD;
&#xD;
          -  Planned chemotherapy or radiation during the 7 days following study initiation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolph Navari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sisters Health System (HSHS) St. Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2021</results_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Rudolph Navari</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>olanzapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03137121/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.&#xD;
Olanzapine: Olanzapine is used as an anti-emetic.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients will receive a placebo orally for 1 to 7 days daily.&#xD;
Placebo: The placebo is a non-anti-emetic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.&#xD;
Olanzapine: Olanzapine is used as an anti-emetic.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients will receive a placebo orally for 1 to 7 days daily.&#xD;
Placebo: The placebo is a non-anti-emetic.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="9"/>
                    <measurement group_id="B2" value="60" spread="11"/>
                    <measurement group_id="B3" value="62" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Nausea Scores</title>
        <description>Daily nausea scores (the primary objective) on day 1 to 7 of treatment for each patient from the Olanzapine and Placebo group will be measured using the Visual Analogue Scale rankings from 0-10 where 0 is no nausea and 10 is the maximum nausea experienced by a patient. A Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that can't be directly measured.&#xD;
Patients will be asked to record the average nausea score for each day in a diary and a study nurse will call the patient at the same time each day to remind the patient to record the nausea score and to inquire about any toxicities. The difference in the nausea scores for the patients in each group (Olanzapine and Placebo) will be compared.</description>
        <time_frame>Nausea score from the Visual Analogue Scale will be recorded each day daily for 7 days. An average value calculated will be reported for the 7 day period.</time_frame>
        <population>One patient withdrew on their own from the Placebo Group</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.&#xD;
Olanzapine: Olanzapine is used as an anti-emetic.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive a placebo orally for 1 to 7 days daily.&#xD;
Placebo: The placebo is a non-anti-emetic.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Nausea Scores</title>
          <description>Daily nausea scores (the primary objective) on day 1 to 7 of treatment for each patient from the Olanzapine and Placebo group will be measured using the Visual Analogue Scale rankings from 0-10 where 0 is no nausea and 10 is the maximum nausea experienced by a patient. A Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that can't be directly measured.&#xD;
Patients will be asked to record the average nausea score for each day in a diary and a study nurse will call the patient at the same time each day to remind the patient to record the nausea score and to inquire about any toxicities. The difference in the nausea scores for the patients in each group (Olanzapine and Placebo) will be compared.</description>
          <population>One patient withdrew on their own from the Placebo Group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1"/>
                    <measurement group_id="O2" value="9" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Emetic Episodes</title>
        <description>The number of emetic episodes (a secondary outcome) by each patient in each group, Olanzapine &amp; Placebo, on each day of treatment will be recorded by each patient on each day of treatment in a diary. A study nurse will contact each patient at the same time of each day of the study to ask the patient to record the number of emetic episodes and report any toxicities.The number of emetic episodes for the patients in each Group for each day of the treatment will be compared.</description>
        <time_frame>Number of emetic episodes for each patient on each day of the seven day treatment.</time_frame>
        <population>One patient withdrew from the Placebo Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.&#xD;
Olanzapine: Olanzapine is used as an anti-emetic.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive a placebo orally for 1 to 7 days daily.&#xD;
Placebo: The placebo is a non-anti-emetic.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Emetic Episodes</title>
          <description>The number of emetic episodes (a secondary outcome) by each patient in each group, Olanzapine &amp; Placebo, on each day of treatment will be recorded by each patient on each day of treatment in a diary. A study nurse will contact each patient at the same time of each day of the study to ask the patient to record the number of emetic episodes and report any toxicities.The number of emetic episodes for the patients in each Group for each day of the treatment will be compared.</description>
          <population>One patient withdrew from the Placebo Group.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-related Adverse Events as Assessed by CTCAE v4.0&quot;.</title>
        <description>Adverse events will be measured by patient-reported outcomes questionnaires and the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A study nurse will contact each patient each day of the seven days of treatment to inquire about any toxicities, specifically sedation and appetite. Sedation and appetite will be reported by the patient in each Group on a Visual Analogue Scale of 0 to 10 with 0 being no sedation or no appetite to 10 indicating maximum sedation or maximum appetite.</description>
        <time_frame>Daily assessment for 7 days for each patient in Olanzapine &amp; Placebo Groups.</time_frame>
        <population>One patient withdrew from Placebo Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.&#xD;
Olanzapine: Olanzapine is used as an anti-emetic.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive a placebo orally for 1 to 7 days daily.&#xD;
Placebo: The placebo is a non-anti-emetic.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-related Adverse Events as Assessed by CTCAE v4.0&quot;.</title>
          <description>Adverse events will be measured by patient-reported outcomes questionnaires and the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A study nurse will contact each patient each day of the seven days of treatment to inquire about any toxicities, specifically sedation and appetite. Sedation and appetite will be reported by the patient in each Group on a Visual Analogue Scale of 0 to 10 with 0 being no sedation or no appetite to 10 indicating maximum sedation or maximum appetite.</description>
          <population>One patient withdrew from Placebo Group.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from baseline through 8 days</time_frame>
      <desc>One patient withdrew from Placebo Group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.&#xD;
Olanzapine: Olanzapine is used as an anti-emetic.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients will receive a placebo orally for 1 to 7 days daily.&#xD;
Placebo: The placebo is a non-anti-emetic.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="21" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rudolph M Navari</name_or_title>
      <organization>Univ Alabama Birmingham</organization>
      <phone>574-261-8385</phone>
      <email>rmnavari@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

